RRM2 and lung adenocarcinoma: reported that RRM2 mRNA expression in lung adenocarcinoma patients was positively correlated with the response to gemcitabine combination therapy, and compared with patients with high RRM2 mRNA expression, those with low RRM2 expression had greater drug sensitivity (57).